Stryker Corporation (NYSE:SYK) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Stryker Corporation (NYSE:SYK) have been assigned an average recommendation of “Moderate Buy” from the twenty-three ratings firms that are currently covering the company, MarketBeat reports. Five investment analysts have rated the stock with a hold recommendation and eighteen have issued a buy recommendation on the company. The average 12 month price objective among brokers that have covered the stock in the last year is $378.1250.

Several research firms have recently commented on SYK. Wall Street Zen upgraded Stryker from a “hold” rating to a “buy” rating in a research note on Saturday, August 8th. Evercore set a $350.00 price objective on shares of Stryker in a research report on Monday, July 6th. Royal Bank Of Canada dropped their price objective on shares of Stryker from $435.00 to $420.00 and set an “outperform” rating on the stock in a research note on Friday, July 31st. Argus set a $370.00 price objective on shares of Stryker in a research report on Thursday, July 9th. Finally, BTIG Research reduced their target price on shares of Stryker from $371.00 to $358.00 and set a “buy” rating for the company in a research note on Friday, July 31st.

Insider Transactions at Stryker

In related news, Director Ronda E. Stryker sold 300,000 shares of the business’s stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $335.90, for a total transaction of $100,770,000.00. Following the sale, the director owned 2,301,375 shares of the company’s stock, valued at approximately $773,031,862.50. The trade was a 11.53% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Dylan Crotty sold 441 shares of the business’s stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $328.61, for a total transaction of $144,917.01. Following the sale, the insider directly owned 6,102 shares in the company, valued at approximately $2,005,178.22. This represents a 6.74% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders sold 351,267 shares of company stock valued at $118,197,701. Corporate insiders own 4.60% of the company’s stock.

Institutional Investors Weigh In On Stryker

Hedge funds and other institutional investors have recently modified their holdings of the stock. Sankala Group LLC purchased a new position in Stryker in the 4th quarter valued at approximately $26,000. Godfrey Financial Associates Inc. acquired a new position in Stryker during the fourth quarter worth $26,000. Gables Capital Management Inc. purchased a new stake in Stryker during the second quarter worth $25,000. Kilter Group LLC purchased a new stake in Stryker during the second quarter worth $25,000. Finally, Cornerstone Financial Management LLC grew its holdings in Stryker by 66.0% in the second quarter. Cornerstone Financial Management LLC now owns 78 shares of the medical technology company’s stock valued at $25,000 after purchasing an additional 31 shares during the last quarter. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Stryker Stock Performance

NYSE SYK opened at $274.80 on Tuesday. The company has a quick ratio of 1.33, a current ratio of 2.16 and a debt-to-equity ratio of 0.59. Stryker has a 52-week low of $267.00 and a 52-week high of $392.55. The business’s 50-day moving average price is $319.92 and its 200 day moving average price is $322.84. The firm has a market cap of $105.40 billion, a P/E ratio of 28.48, a P/E/G ratio of 1.74 and a beta of 0.76.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Thursday, July 30th. The medical technology company reported $3.69 EPS for the quarter, beating the consensus estimate of $3.49 by $0.20. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The firm had revenue of $6.59 billion during the quarter, compared to the consensus estimate of $6.58 billion. During the same period in the prior year, the business earned $3.13 EPS. The firm’s revenue was up 9.4% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. On average, equities research analysts expect that Stryker will post 15 earnings per share for the current year.

Stryker Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be issued a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 1.3%. The ex-dividend date of this dividend is Wednesday, September 30th. Stryker’s dividend payout ratio is currently 36.48%.

About Stryker

Stryker Corporation is a global medical technology company headquartered in Portage, Michigan. The company develops and manufactures products used by hospitals, physicians and other healthcare providers across a range of medical specialties.

Stryker’s principal businesses include orthopaedics, medical and surgical equipment, and neurovascular products. Its offerings include joint replacement and trauma implants, spinal devices, surgical instruments, operating-room equipment, endoscopy systems, surgical navigation technologies, emergency-care products and devices used to treat neurovascular conditions such as stroke.

Founded in 1941 by Dr.